Retatrutide vs Tirzepatide 2026: Triple Agonist vs Mounjaro Compared for Vietnam Buyers
Last updated April 2026
24.2%
Retatrutide 48-week avg
22.5%
Tirzepatide 72-week avg
Varies
priced by vial; research-grade figure from Peptara Labs
You have been on tirzepatide for eight months in HCMC. The first stretch came off fast. The last few kilos have taken twice as long. You have hit the plateau everyone warned you about, and now a friend in the expat health group keeps mentioning retatrutide. He says the switch restarted his loss. You want to know if it is worth the upgrade, or if you should just push through on tirzepatide.
This is the actual question people are asking. Not the clinical-journal version. The practical, I-live-in-Vietnam, I-source-both-compounds version. This guide answers that.
Both drugs work. Both have a following in Vietnam, and both reach people here as research-grade vials rather than pharmacy pens. The real question is which one fits your situation, and where the tradeoffs actually matter. Let's get into it.
On this page
Quick Comparison
| Factor | Retatrutide | Tirzepatide |
|---|---|---|
| Receptor Mechanism | GLP-1 + GIP + Glucagon (triple) | GLP-1 + GIP (dual) |
| Receptors | 3 | 2 |
| Avg Weight Loss | 24.2% at 48 weeks | 22.5% at 72 weeks |
| Study Name | Phase 2 obesity trial (NEJM 2023) | SURMOUNT trial |
| Half-life | ~6 days | ~5 days |
| FDA Status | Phase 3 trials | FDA approved (Mounjaro/Zepbound) |
| Dosing | Once weekly | Once weekly |
| Availability | Research-grade only | Research-grade only (no registered pharmacy route) |
| Cost (Vietnam) | Message Peptara Labs, per vial | Message Peptara Labs, per vial |
Bottom line: The two columns above are not a head to head. Retatrutide and tirzepatide have not yet been compared in a trial that has reported (TRIUMPH-5 is still running on ClinicalTrials.gov), so their weight loss figures come from separate studies with different designs, populations, and timeframes. What can be said plainly is that tirzepatide has the longer safety record and regulatory approval behind it, and that retatrutide does not. That approval comes with label dose steps, laid out in our tirzepatide dosage guide.
The Short Answer for Vietnam Buyers
If maximum weight loss is the goal: retatrutide. Its phase 2 trial reported 24.2% average weight loss at 48 weeks, and its phase 3 TRIUMPH-1 trial, published in the New England Journal of Medicine in 2026, reported -25.0% in the highest dose group versus -3.9% on placebo at 80 weeks for the treatment-regimen estimand. Those were separate trials from the tirzepatide ones, so it is a comparison of published averages, not a proven advantage. If you have already plateaued on tirzepatide or are starting fresh with an aggressive target, this is the molecule people look at next.
If proven track record and supply reliability matter: tirzepatide. Mounjaro holds no Vietnamese marketing registration, so the research-grade route is the one that exists here. Research-grade tirzepatide is widely available here. Four years of real-world safety data.
For most expats reading this: the answer depends on goal size, access preference, and risk tolerance, and it is not one a web page can settle for an individual. What follows sets out what the published evidence and the Vietnam access picture cover for each compound, so those trade-offs can be weighed with a prescriber.
Sources: TRIUMPH-1, New England Journal of Medicine, 29 September 2026
How They Work
Tirzepatide and retatrutide belong to the same broad class (incretin mimetics) but activate a different number of receptors. Tirzepatide hits two. Retatrutide hits three. That one extra receptor changes the whole metabolic profile of the drug.
For the dual agonists that pair GLP-1 with glucagon instead of GIP, see mazdutide vs retatrutide.
GLP-1 and GIP (the two receptors tirzepatide targets) primarily work on appetite and insulin response. They signal satiety to the brain, slow gastric emptying so you feel full longer, and improve glucose disposal. The weight loss is driven almost entirely by eating less. Tirzepatide does not directly change how much energy your body burns at rest.
Retatrutide adds the glucagon receptor. Glucagon in this context is not the blood sugar rescue hormone most people know. When pulsed chronically through a peptide drug, glucagon activates hepatic (liver) fat oxidation, increases basal metabolic rate, and shifts the body toward burning stored fat as fuel even at rest. That third receptor is the proposed mechanism behind the weight loss averages reported in the retatrutide trial. Because the two compounds have never been compared in the same trial, the real size of any difference between them is unknown.
Tirzepatide
Mounjaro / Zepbound, Dual Agonist
- GLP-1: Reduces appetite, slows gastric emptying
- GIP: Enhances insulin response, reduces GLP-1 nausea
- Pivotal trials: SURMOUNT-1, SURMOUNT-2
- FDA approved 2022 (diabetes), 2023 (weight loss) [14]
- Average weight loss: 22.5% at 72 weeks [2]
- Maximum reported: 26.6% in top dose group [3]
Retatrutide
Triple Agonist, Phase 3 Trials
- GLP-1: Appetite suppression (same as Tirzepatide)
- GIP: Insulin enhancement (same as Tirzepatide)
- Glucagon: Hepatic fat oxidation, raises metabolic rate
- Pivotal trials: TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, TRIUMPH-4
- Phase 3 TRIUMPH-1 published in NEJM, September 2026
- Phase 2 published in NEJM June 2023
- Average weight loss: 24.2% at 48 weeks [4]
Sources: Jastreboff et al., NEJM 2023 (retatrutide Phase 2), SURMOUNT-1 NEJM 2022, TRIUMPH-1 trial registration.
Sources: TRIUMPH registrational trial design, Diabetes, Obesity and Metabolism, 2026; TRIUMPH-1, New England Journal of Medicine, 29 September 2026
Weight Loss Results Compared
Tirzepatide results come from Phase 3 data, the SURMOUNT trial program, which is the gold standard for obesity drug evidence. Retatrutide now has Phase 3 data too: TRIUMPH-1, published in the New England Journal of Medicine on 29 September 2026, reported a mean weight change of -25.0% in its highest dose group versus -3.9% on placebo at 80 weeks, for the treatment-regimen estimand. The table below keeps the earlier Phase 2 timepoints from Jastreboff and colleagues in NEJM in 2023; TRIUMPH-1 ran 80 weeks, not 72, so the 72-week row shows its 80-week figure with that label.
| Timeframe | Retatrutide | Tirzepatide |
|---|---|---|
| 12 weeks | ~10% | ~8% |
| 24 weeks | ~18% | ~15% |
| 48 weeks | 24.2% (Phase 2) | ~20% |
| 72 weeks | 25.0% at 80 weeks (Phase 3, TRIUMPH-1) | 22.5% (Phase 3) |
The two columns are not a head to head. Retatrutide and tirzepatide have not yet been compared in a trial that has reported (TRIUMPH-5 is still running on ClinicalTrials.gov), so the figures above are drawn from separate programs with different populations, designs, and endpoints, lined up here for reference rather than as a contest. Nothing in that table establishes that one compound beats the other.
Individual variation is large on both drugs. Every trial in this class reports low responders who stall well short of the average and high responders who go well past it, and this page does not put a share of the population on either group. The numbers in the table are means, not guarantees, and a mean says nothing about where any one person lands.
Community reports from Vietnam expats broadly echo the shape of the trial data, but they are not data. People who switch compounds after a plateau sometimes report that loss restarts for a while, and people starting fresh often describe a fast early phase. This page does not attach numbers to those reports, because there are none measured under any protocol worth attaching.
Sources: ClinicalTrials.gov, TRIUMPH-5, NCT06662383; TRIUMPH-1, New England Journal of Medicine, 29 September 2026; Eli Lilly, TRIUMPH-1 results and trial design, 21 May 2026
Side Effects: Real-World Comparison
Side effects are the number one reason people quit GLP-1 drugs, not efficacy.5 Tirzepatide and retatrutide share most of the same side effects.6 Here is the honest breakdown, including the parts this page will not put a number on.
GI effects (nausea, diarrhea, constipation). Gastrointestinal effects are the most commonly reported side effects for both compounds, with nausea the most frequent of them. This page does not publish incidence rates for either: the two were studied in separate trials with different populations, designs, and reporting conventions, so the rates are not comparable across them, and quoting one against the other would invent a comparison that no trial has made. In both trial and community reports, these effects are described as most intense early on and easing from there.
Injection site reactions. Minor redness or itching at the injection site is an uncommon but recognised complaint on either compound, and it is usually a technique issue rather than the compound itself. The specifics of technique are something to learn from a physician or another qualified source. Reactions almost always resolve within 24 hours.
Heart rate. Both compounds reported small mean increases in heart rate in their trial data, and a mean increase is also noted on the approved tirzepatide labelling, so this is not a point of difference between them.7 The reported sizes come from separate trials and are not comparable across them, which is why no numbers are quoted here. If you have an underlying heart condition, or you track heart rate on a wearable and see a change, that belongs in front of a physician rather than being weighed up on a web page.
Gallbladder risk. Both drugs carry an elevated gallstone risk that scales with total weight loss. Users losing over 20 percent of body weight have measurably higher gallstone incidence regardless of compound.8 If you have a history of gallbladder issues, discuss with a physician before starting either.
Muscle loss. Any rapid weight loss drug carries a muscle loss concern. Retatrutide's more aggressive fat oxidation profile amplifies this if protein intake and resistance training are neglected. How much of each you need is worth setting with a physician or a qualified coach who has your numbers in front of them, rather than copying a generic target off the internet.
Micronutrient monitoring. Both drugs reduce food intake significantly, which can lead to B12, iron, and vitamin D deficiencies over months of use. Periodic bloodwork is worth arranging with a physician, especially on retatrutide where caloric intake drops harder in the first phase.
For more on what people do to blunt GI side effects on either drug, see the GLP-1 side effects management guide.15
What the Evidence Covers for Each Compound
The three cards below record what the published trial evidence and the Vietnam access picture cover for each compound. None of them is a recommendation. Whether any compound is appropriate for a specific person is a question for a licensed prescriber who has that person's history in front of them.
What the Retatrutide Evidence Covers
- Phase 3 results now published (TRIUMPH-1 in NEJM, TRIUMPH-2 in The Lancet, September 2026), still not a head to head
- Adds glucagon receptor activation on top of the GLP-1 and GIP action tirzepatide has
- Still in Phase 3 (TRIUMPH), not approved by any regulator [9]
- Reaches Vietnam research-grade only, with no pharmacy route anywhere
- Side effect profile rests on less published data than the tirzepatide one
- Restarted loss after a tirzepatide or semaglutide plateau is a community report, not something any trial has tested
What the Tirzepatide Evidence Covers
- FDA approved for diabetes in 2022 and for obesity in 2023 [10]
- Phase 3 evidence base (the SURMOUNT program), the strongest in this comparison
- Average weight loss of 22.5% at 72 weeks in SURMOUNT-1 [2]
- Over three years of post-approval real-world safety data
- Dual agonist: GLP-1 and GIP, without the glucagon arm
- No Vietnamese marketing registration for the branded product, so no registered pharmacy route exists here
What the Semaglutide Evidence Covers
- The most studied compound in this class, with the longest published track record
- Acts on the GLP-1 receptor alone, without the GIP or glucagon arms
- Approved earlier than tirzepatide, while retatrutide holds no approval anywhere [11]
- Branded semaglutide reaches pharmacy channels in some markets, and availability varies by country
- Widely used as an entry point to the GLP-1 class, which is a usage pattern rather than a clinical ranking
- Its own trial figures sit in the semaglutide profile rather than on this page
See the semaglutide profile or the Vietnam pricing guide.
Sources: TRIUMPH-2, The Lancet, 29 September 2026; TRIUMPH-1, New England Journal of Medicine, 29 September 2026
Dosing Comparison
This page does not publish dose amounts, escalation steps, or a week-by-week schedule for either compound. What follows is the regulatory difference between the two, not guidance on how either one is used.
That difference is entirely regulatory. Tirzepatide has an approved label, with a defined path set out behind it by regulators and a prescriber to interpret it.12 Retatrutide has no approved label anywhere, only trial protocols, so it has no approved dose: its phase 3 trials assigned fixed arms under monitoring, and no regulator has yet reviewed them. In plain terms, one of these compounds has an official answer to the dosing question and the other does not, which is precisely why the answer for any individual belongs with a licensed prescriber rather than a page like this one. Once a doctor has set a dose, our tirzepatide vial calculator can do the math.
Plateaus happen on both compounds, and they usually reflect adaptive metabolic slowdown rather than a failure of the drug. What to do about one, including whether anything about the dose should change at all, is a conversation for a qualified prescriber, not a decision to take from a web page.
Sources: TRIUMPH-1, New England Journal of Medicine, 29 September 2026
Vietnam-Specific Considerations
This section is why this guide exists. Most comparison articles online are written for US or UK readers. Here is what actually matters if you are buying either drug in Vietnam.
Access. Mounjaro (tirzepatide) holds no Vietnamese marketing registration, so no pharmacy here dispenses it and the research-grade route is the one that exists. Retatrutide is research-grade only. No pharmacy in Vietnam stocks retatrutide, and there is no registered product for it here to stock.
Pricing in Vietnam. Branded Mounjaro and Zepbound hold no Vietnamese marketing registration, so there is no registered pharmacy price to quote for tirzepatide.13 For research-grade supply, this guide points to Peptara Labs, which prices each compound by vial rather than by month, so no number is quoted here for either and a current figure comes from asking them. That also means the two cannot be lined up against each other on a per milligram basis here. How long any vial lasts is a clinical question, not something this page will put a number on.
Cold chain considerations. HCMC and Hanoi summer temperatures regularly hit 35 to 40 Celsius. Both compounds require refrigeration between 2 and 8 Celsius. Shipping with gel packs in insulated packaging is non-negotiable. Unreconstituted retatrutide is slightly more heat-stable in lyophilized form than reconstituted tirzepatide in solution, but neither will survive a day in a hot car or a non-refrigerated hotel mini-fridge. Always request express shipping during Vietnamese summer.
Customs considerations. Research-grade compounds shipped from international suppliers (China, EU, US) cross customs on entry. This page makes no prediction about how any given shipment is treated, and nobody should read someone else's uneventful delivery as a rule. Domestic Vietnamese suppliers do not cross a border at all, which is one reason many people here use them. Full legal context is in the peptide legality guide.
Physician oversight. There is no registered pharmacy route for tirzepatide in Vietnam, so both compounds on this page reach you research-grade, and both are worth baseline labs before you start. FV Hospital and Vinmec in both cities have endocrinologists who understand GLP-1s and can run those labs and monitor you. The HCMC peptide guide and Hanoi peptide guide cover physician options in each city.
Why people usually meet tirzepatide first. The common pattern in the Vietnam expat community is that tirzepatide is the first of the two people encounter, and the reason is history rather than strategy. It has been around longer and is far more widely used. If tirzepatide works well and results are sufficient, people stay there. Whether to change compound at all, and when, is a prescriber's call, not a community default.
The Verdict
The table below sorts this guide's comparison by goal, so the trial data and the Vietnam supply picture can be read one line at a time. It records what the evidence points to for each goal rather than what any one reader should take: appropriateness for a specific person remains a question for a licensed prescriber.
| Goal | Where the Evidence Points |
|---|---|
| Maximum weight loss | Retatrutide |
| Most safety data | Tirzepatide |
| FDA-approved option | Tirzepatide |
| Already plateaued on GLP-1 | Retatrutide |
| First-time GLP-1 user | Tirzepatide (or semaglutide) |
| Already in Vietnam long-term | Retatrutide (supply reliable) |
| Tourist or short-term visit | Tirzepatide (supply brought from home) |
Both compounds have real evidence behind them, which is why the table splits by goal instead of naming one winner: the trade-offs run in different directions, weight-loss magnitude against length of safety record, and access route against approval status. The magnitude column rests on figures from separate trials, never a head to head, so read it as where the published evidence sits rather than as a contest one compound won. For a deeper clinical view, this side-by-side comparison of the two compounds lines up the trial data point by point.
What Vietnam Users Report
The following patterns come from community reports in Vietnam expat health groups through 2025 and 2026. These are anecdotal, not clinical claims.
The most consistent pattern reported is the tirzepatide to retatrutide switch. People who plateau on tirzepatide and later move to retatrutide often report that loss restarts for a period. No figures are attached to that here: community reports are not measured under any protocol, and the numbers people quote to each other are not evidence of anything.
The second pattern is how the early weeks feel. Many first-time retatrutide users describe more intense nausea and appetite loss early on than they remember from tirzepatide, easing after the first stretch. People who switched often call retatrutide "more noticeable" rather than "worse." Those are impressions rather than measurements, and since the two compounds have never been studied in the same trial, there is nothing to check them against.
The third pattern is cost. Neither has a fixed research-grade price on this page, and people weigh cost against how each one has worked for them. This page will not put a total on a weight loss journey. That depends on the individual, how long they stay on anything, and clinical decisions that are not ours to make.
Availability in Vietnam
Peptara Labs
COA-verified retatrutide and tirzepatide with cold-chain shipping across Vietnam. See the supply page for sourcing criteria.
Frequently Asked Questions
Is tirzepatide better than retatrutide?+
Tirzepatide is better if you want a proven, FDA-approved medication with 3+ years of real-world data, though that pharmacy shelf is a US one: Mounjaro holds no Vietnamese marketing registration, so there is no registered pharmacy route for it here. Retatrutide is better if you want maximum weight loss and can accept research-grade status with less long-term safety data. No head to head result has been published yet: ClinicalTrials.gov lists TRIUMPH-5 (NCT06662383), a trial of retatrutide against tirzepatide in about 800 people with an 80-week weight endpoint, as active, not recruiting, with primary completion estimated for November 2026. Until it reports, their weight loss figures come from separate trials with different designs and timeframes and cannot be read as a head to head. "Better" depends entirely on whether you prioritize regulatory safety or maximum results.
Which is stronger, retatrutide or tirzepatide?+
No head to head result exists yet, because ClinicalTrials.gov lists the trial comparing them, TRIUMPH-5 (NCT06662383), as still running, so this can only be answered by lining up separate trials. The retatrutide Phase 2 trial (Jastreboff et al., NEJM 2023) reported up to 24.2% average weight loss at 48 weeks in its highest dose arm, and 83% of that group lost at least 15%. The retatrutide phase 3 TRIUMPH-1 trial, published in the New England Journal of Medicine in 2026, then reported a mean weight change of -25.0% in its highest dose group versus -3.9% on placebo at 80 weeks, for the treatment-regimen estimand. The tirzepatide Phase 3 program (SURMOUNT-1) reported around 22.5% at 72 weeks. Different trials, different populations, different timeframes, so read that as two published averages rather than a proven ranking. Retatrutide does add glucagon receptor activation, which increases energy expenditure on top of the appetite suppression both drugs share.
Does retatrutide work faster than tirzepatide?+
No head to head trial has reported yet, with TRIUMPH-5 still running on ClinicalTrials.gov, so there is no clean answer. Early timepoint figures for the two come from separate studies and are not comparable across them, which is why this page does not rank the two on speed. Both follow a steady curve measured in months rather than producing overnight changes.
Can you switch from tirzepatide to retatrutide?+
Switching between GLP-1 compounds is a common question in the Vietnam expat community. This page does not describe how such a change is made. Whether to switch at all, when, and what any change would involve are decisions for a licensed prescriber who has your history in front of them.
How much weight can I lose on retatrutide vs tirzepatide?+
Only as published averages, never as a personal prediction. For a 90kg person, the 22.5% tirzepatide average over 72 weeks works out to roughly 20kg, and the 24.2% retatrutide average over 48 weeks to roughly 22kg. Those two averages come from separate trials over different timeframes, so lining them up is not a head to head. Individual variation is large. Responders on either drug can exceed these averages. Non-responders on either drug plateau earlier. Adherence and concurrent lifestyle factors also affect the outcome.
Is retatrutide FDA approved?+
Not yet. Retatrutide is in Phase 3 clinical trials (the TRIUMPH program) as of 2026. This page makes no prediction about when, or whether, an approval follows. For now, retatrutide is research-grade only. It is not sold in pharmacies in any country. Tirzepatide was FDA approved for diabetes in 2022 (Mounjaro) and for obesity in 2023 (Zepbound).
How much does retatrutide cost in Vietnam?+
There is no pharmacy option in Vietnam for retatrutide, and this page will not quote a figure for it. For the research-grade route, Peptara Labs sells it by the vial. The honest answer is to message them for a current number rather than read one off a table.
How much does tirzepatide cost in Vietnam?+
Branded Mounjaro and Zepbound hold no Vietnamese marketing registration, so there is no registered pharmacy price to quote for either. For research-grade tirzepatide this guide points to Peptara Labs, where the cost depends on vial size. Ask them for a current price rather than expect a fixed one. It cannot be set against retatrutide on a per milligram basis either, since no fixed vial price is published here.
Which has worse side effects, retatrutide or tirzepatide?+
No head to head safety comparison has been published yet, with TRIUMPH-5 still running on ClinicalTrials.gov, so there is no reliable ranking to give. Both report gastrointestinal effects, nausea most commonly, and both are described in their trials as most intense early on and easing with time. Both carry the same serious warnings (thyroid concerns, pancreatitis, gallbladder). Both have also reported small mean heart rate increases in their respective trials. What any of that means for you is a question for a physician who knows your history.
Sources: ClinicalTrials.gov, TRIUMPH-5, NCT06662383; TRIUMPH-1, New England Journal of Medicine, 29 September 2026
Harm reduction education, not medical advice
This guide compares clinical data and community experience to help you make an informed decision. It is not a prescription recommendation. Talk to a doctor before starting either compound.
Related Guides
This guide is for educational purposes only. Consult a healthcare professional before starting any peptide protocol.
Sources
Entries marked ° are cited from the publisher, but our checker could not retrieve the page to confirm the wording.
- 1.PubMed PMID 40741227
- 2.PubMed PMID 35658024
- 3.PubMed PMID 37840095
- 4.PubMed PMID 37436564
- 5.PubMed PMID 29033597
- 6.PubMed PMID 39507873
- 7.PubMed PMID 37366315
- 8.PubMed PMID 39468292
- 9.PubMed PMID 41090431
- 10.PubMed PMID 39794609
- 11.PubMed PMID 39761578
- 12.accessdata.fda.gov / drugsatfda docs label 2022 215866s000lbl.pdf°
- 13.vietnamnet.vn / but tiem giam can chua duoc cap phep o viet nam 2532258.html
- 14.fda.gov / news events press announcements fda approves new medication chronic weight
- 15.PubMed PMID 34775881
- 16.ClinicalTrials.gov, TRIUMPH-5, NCT06662383
- 17.TRIUMPH-2, The Lancet, 29 September 2026
- 18.TRIUMPH-1, New England Journal of Medicine, 29 September 2026
- 19.Eli Lilly, TRIUMPH-1 results and trial design, 21 May 2026